IVD Department Qualitative Antibody Test for HTLV-I and HTLV-II - Vietnam Registration 2403239ĐKLH/BYT-HTTB
Access comprehensive regulatory information for IVD Department Qualitative Antibody Test for HTLV-I and HTLV-II in Vietnam's medical device market through Pure Global AI's free database. This Risk Class TTBYT Loại D medical device is registered under number 2403239ĐKLH/BYT-HTTB and manufactured by Abbott GmbH. The authorized representative in Vietnam is VĂN PHÒNG ĐẠI DIỆN ABBOTT LABORATORIES GMBH TẠI THÀNH PHỐ HÀ NỘI.
This page provides complete technical specifications, regulatory compliance details. Pure Global AI offers free access to 300,000+ Vietnamese medical device registrations, helping global MedTech companies navigate Vietnam MOH regulations, identify competitors, and discover partnership opportunities efficiently.
Device Details
Registration Details
2403239ĐKLH/BYT-HTTB
000.00.04.G18-231201-0014
Theo theo phụ lục
Theo phụ lục
Technical Details
The ARCHITECT rHTLV-I/II calibrator is used to calibrate the ARCHITECT iSystem when performing qualitative detection of HTLV-I and HTLV-II antibodies in human serum and plasma. Refer to the ARCHITECT rHTLV-I/II Assay User Manual and the ARCHITECT System Operations Manual for more information. The ARCHITECT rHTLV-I/II control material is used to assess the accuracy of the test and to detect systematic analytical deviation of the ARCHITECT iSystem when performing qualitative detection of HTLV-I and HTLV-II antibodies in human serum and plasma. Refer to the ARCHITECT rHTLV-I/II Assay User Manual and the ARCHITECT System Operations Manual for more information. The ARCHITECT rHTLV-I/II is a fluorescent bead-based immunoassay (CMIA) for qualitative detection of HTLV-I and HTLV-II antibodies in human serum and plasma, including samples collected from patients who have no pulse (cardiac arrest). The ARCHITECT rHTLV-I/II test is used to support the diagnosis of HTLV-I and HTLV-II infections, and is used as a screening test to prevent the transmission of HTLV-I and HTLV-II infected blood, blood components, cells, tissues, and organs.
Dates and Status
Nov 02, 2024

